Toggle light / dark theme

Scientists stress that the symptoms of space travel aren’t exactly the same as aging, and many changes reverse themselves once people return to Earth, but the comparisons are still useful. Spaceflight is an immersive experience that spares no traveler, while aging happens to every Earthling whether we like it or not. As such, life in space is a good model for understanding aging as a chronic process, Bailey says. The barren otherworld of outer space could even reveal new ways to protect ourselves against the process of growing old.


Space travel induces bodily changes that are remarkably similar to growing old, providing a unique way to boost medical research.

Longevity biotech firm BioAge Labs is readying itself for clinical trials after raising a whopping $90 million Series C funding round. The company revealed it will be moving its lead platform-derived therapies, BGE-117 and BGE-175, into Phase 2 clinical trials in the first half of 2021.

Longevity. Technology: As the developer of an AI platform that maps the molecular pathways impacting human Longevity, we’ve followed developments at BioAge with great interest. With two compounds ready to enter the clinic next year, and more on the way, this company is fast-becoming one of Longevity’s most exciting prospects.

The new funds will be used to develop BioAge’s portfolio of therapies for increasing healthspan and lifespan, as well as to augment its AI platform, and further expand its capabilities to test drug candidates in predictive models of human diseases of aging.

Sounds important.


Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.

The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against .

“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”

After controlling for various factors — such as participants’ age, sex, smoking status and activity level — the researchers found that taking glucosamine/chondroitin every day for a year or longer was associated with a 39 percent reduction in all-cause mortality.

It was also linked to a 65 percent reduction in cardiovascular-related deaths. That’s a category that includes deaths from stroke, coronary artery disease and heart disease, the United States’ biggest killer.” “He explains that because this is an epidemiological study — rather than a clinical trial — it doesn’t offer definitive proof that glucosamine/chondroitin makes death less likely. But he does call the results “encouraging.””.


Glucosamine supplements may reduce overall mortality about as well as regular exercise does, according to a new epidemiological study from West Virginia University.

“Does this mean that if you get off work at five o’clock one day, you should just skip the gym, take a glucosamine pill and go home instead?” said Dana King, professor and chair of the Department of Family Medicine, who led the study. “That’s not what we suggest. Keep exercising, but the thought that taking a pill would also be beneficial is intriguing.”

He and his research partner, Jun Xiang — a WVU health data analyst — assessed data from 16,686 adults who completed the National Health and Nutrition Examination Survey from 1999 to 2010. All of the participants were at least 40 years old. King and Xiang merged these data with 2015 mortality figures.